logo-loader
viewCardiol Therapeutics

Cardiol Therapeutics says its nanotechnology successfully delivers anti-fibrotic drugs to diseased heart

Results showed an exponential increase in the uptake of Cardiol’s nanoparticles in heart failure hearts compared to a control group

Cardiol Therapeutics -
Cardiol is focused on producing pharmaceutical cannabidiol products and developing innovative therapies for heart diseases

Cardiol Therapeutics Inc (TSE:CRDL) (OTCQX:CRTPF) announced promising new study data on Tuesday highlighting the effectiveness of its nanotechnology approach to drug delivery.

Results showed that there was an exponential increase in the uptake of Cardiol’s nanoparticles in heart failure hearts compared to a control group in a pre-clinical model of non-ischemic heart failure.

Nanoparticles preferentially gathered within cells in fibroblasts, indicating the potential to successfully deliver anti-fibrotic drugs such as cannabidiol to the diseased area of the heart.

READ: Cardiol Therapeutics shares positive new study results supporting lead drug’s ability to protect against heart failure

According to the study, the nanoparticles localized within the diseased hearts in areas known as fibrosis, which is largely responsible for the stiffening and reduced function of the heart muscle.

The data provides new insights into how nanotherapeutics could be used to target the anti-fibrotic properties of cannabidiol to fibrous tissue in a failing heart, according to Dr Arvind Bhimaraj, interim division chief of the Division of Heart Failure and co-director of the Heart Failure Translational Research Laboratory at Houston Methodist DeBakey Heart & Vascular Center, where the study was conducted.

Dr Bhimaraj is a member of the Clinical Steering Committee for Cardiol's planned international clinical trial in acute myocarditis.

"The specific targeting of the fibrotic tissue in the heart offers the potential to utilize drugs more effectively to prevent the progression of heart failure,” Bhimaraj said in a statement.

Data from the study was accepted for presentation at the American College of Cardiology's 69th Annual Scientific Session & Expo together with the World Congress of Cardiology, held virtually at the end of March.

Cardiol is focused on producing pharmaceutical cannabidiol products and developing innovative therapies for heart diseases, including acute myocarditis and other causes of heart failure. Its proprietary nanotechnology is designed to enable the distribution of water-insoluble drugs within the blood circulation, improve pharmacokinetics, and facilitate drug accumulation in the failing heart.

The company is planning an international clinical trial of its flagship drug CardiolRx in acute myocarditis, which is caused by inflammation in heart tissue.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: Cardiol Therapeutics

Price: 2.1 CAD

TSX:CRDL
Market: TSX
Market Cap: $68.85 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cardiol Therapeutics named herein, including the promotion by the Company of Cardiol Therapeutics in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Cardiol Therapeutics signs supply agreement with Medical Cannabis by Shoppers

Cardiol Therapeutics ((TSX: CRDL; OTCQX: CRTPF) CEO David Elsley joined Steve Darling from Proactive to discuss the company announcing a supply agreement with Medical Cannabis by Shoppers.  Elsley discusses what this deal means for the company having a name like Shoppers associated with...

on 03/19/2020

2 min read